{"pmid":32473311,"title":"Angiotensin receptor blockers for the treatment of covid-19 and its comorbidities.","text":["Angiotensin receptor blockers for the treatment of covid-19 and its comorbidities.","Pharmacol Res","Saavedra, Juan M","32473311"],"journal":"Pharmacol Res","authors":["Saavedra, Juan M"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473311","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.phrs.2020.104958","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668255193298370561,"score":9.490897,"similar":[{"pmid":32394850,"title":"[Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].","text":["[Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].","The review addressed the relationship of coronavirus disease 2019 (COVID-19) with functioning of the renin-angiotensin-aldosterone axis and the causes for unfavorable prognosis depending on patients' age and comorbidities. The authors discussed in detail potential effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists on the risk of infection and the course of COVID-2019 as well as the effect of SARS-COV2 virus on the cardiovascular system.","Kardiologiia","Mareev, Yu V","Mareev, V Yu","32394850"],"abstract":["The review addressed the relationship of coronavirus disease 2019 (COVID-19) with functioning of the renin-angiotensin-aldosterone axis and the causes for unfavorable prognosis depending on patients' age and comorbidities. The authors discussed in detail potential effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists on the risk of infection and the course of COVID-2019 as well as the effect of SARS-COV2 virus on the cardiovascular system."],"journal":"Kardiologiia","authors":["Mareev, Yu V","Mareev, V Yu"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32394850","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.18087/cardio.2020.4.n1122","e_drugs":["Aldosterone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666627827848445954,"score":64.43925},{"pmid":32304747,"pmcid":"PMC7158830","title":"Angiotensin receptor blockers and COVID-19.","text":["Angiotensin receptor blockers and COVID-19.","Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients.","Pharmacol Res","Saavedra, Juan M","32304747"],"abstract":["Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients."],"journal":"Pharmacol Res","authors":["Saavedra, Juan M"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304747","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.phrs.2020.104832","keywords":["ace2","angiotensin receptor blockers","covid-19","coronavirus","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491087486979,"score":63.849304},{"pmid":32430049,"title":"Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score.","text":["Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score.","Crit Care","Vavougios, George D","32430049"],"journal":"Crit Care","authors":["Vavougios, George D"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32430049","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1186/s13054-020-02903-9","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288309714944,"score":61.236954},{"pmid":32385549,"title":"COVID-19, Angiotensin Receptor Blockers, and the Brain.","text":["COVID-19, Angiotensin Receptor Blockers, and the Brain.","Cell Mol Neurobiol","Saavedra, Juan M","32385549"],"journal":"Cell Mol Neurobiol","authors":["Saavedra, Juan M"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385549","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s10571-020-00861-y","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666340102005063680,"score":61.097565},{"pmid":32129518,"title":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","text":["Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.","At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.","Drug Dev Res","Gurwitz, David","32129518"],"abstract":["At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility."],"journal":"Drug Dev Res","authors":["Gurwitz, David"],"date":"2020-03-05T11:00:00Z","year":2020,"_id":"32129518","source":"PubMed","week":"202010|Mar 02 - Mar 08","doi":"10.1002/ddr.21656","keywords":["at1r blockers","covid-19 epidemic","sars-cov-2","angiotensin-converting enzyme 2 (ace2)","losartan"],"locations":["losartan"],"e_drugs":["Losartan"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490723631104,"score":60.70618}]}